Update: September 2022
Forms and strengths
-
400 mg tablet
-
100 mg dispersible tablet, to be dispersed in 10 ml water
Dosage (standard dose)
-
Child under 30 kg: 10 to 15 mg/kg once daily
-
Child 30 kg and over and adult: 400 mg once daily
-
Maximum dose: 400 mg daily
|
Weight |
Daily dose |
400 mg tablet |
100 mg dispersible tablet |
|---|---|---|---|
|
5 |
50-75 |
− |
7 ml |
|
6 |
60-90 |
− |
7 ml |
|
7 |
70-105 |
− |
1 tab |
|
8 |
80-120 |
− |
1 tab |
|
9 |
90-135 |
− |
1 tab |
|
10 |
100-150 |
− | 2 tab |
|
11 |
110-165 |
− | 2 tab |
|
12 |
120-180 |
− | 2 tab |
|
13 |
130-195 |
− | 2 tab |
|
14 |
140-210 |
− | 2 tab |
|
15 |
150-225 |
− | 2 tab |
|
16 |
160-240 |
− | 3 tab |
|
17 |
170-255 |
− | 3 tab |
|
18 |
180-270 |
− | 3 tab |
|
19 |
190-285 |
− | 3 tab |
|
20 |
200-300 |
− | 3 tab |
|
21 |
210-315 |
− | 3 tab |
|
22 |
220-330 |
− | 3 tab |
|
23 |
230-345 |
− | 3 tab |
|
24 |
240-360 |
− | 4 tab |
|
25 |
250-375 |
− | 4 tab |
|
26 |
260-390 |
− | 4 tab |
|
27 |
270-405 |
− | 4 tab |
|
28 |
280-420 |
− | 4 tab |
|
29 |
290-435 |
− | 4 tab |
|
|
|||
|
30-35 |
400 |
1 tab |
− |
|
36-45 |
400 |
1 tab |
− |
|
46-55 |
400 |
1 tab |
− |
|
56-70 |
400 |
1 tab |
− |
|
> 70 |
400 |
1 tab |
− |
Contra-indications, adverse effects, precautions
- Do not administer to patients with hypersensitivity reaction or tendon damage during a previous treatment with a fluoroquinolone.
- Administer with caution to patients:
- over 60 years or on corticosteroid treatment (increased risk of tendon damage);
- with diabetes or history of psychiatric disorders or seizures.
- May cause:
- tendinitis, tendon rupture, moderate QT prolongation;
- gastrointestinal disturbances (abdominal or epigastric pain, diarrhoea);
- nervous system or psychiatric disorders (headache, seizures, psychosis, etc.);
- photosensitivity;
- hypersensitvity reactions, hypo/hyperglycaemia;
- rarely: crystalluria, peripheral neuropathy, ototoxicity.
- For the management of adverse effects, see Appendix 17.
- Avoid or use with caution and under close monitoring in patients taking other QT prolonging drugs (Appendix 19) or warfarin.
- Do not administer simultaneously with antacids containing magnesium/aluminium, calcium, iron and zinc salts (administer 2 hours apart).
- Pregnancy:
-
DR-TB: use if the benefits outweigh the risks (safety not established).
-
DS-TB: do not use.
-
- Breastfeeding:
-
DR-TB: avoid breastfeeding during treatment (no absolute contra-indication).
-
DS-TB: avoid breastfeeding during treatment.
-
Monitoring
- Symptomatic monitoring
Patient instructions
- Take 2 hours apart from milk-based product, antacids, calcium, iron and zinc salts.
- 100 mg tablets should be dispersed in 10 ml water.
- Maintain a good fluid intake.
- Protect your skin from sun.
Remarks
-
High dose moxifloxacin (Mfxh), i.e. 600 to 800 mg once daily in patients over 30 kg may be used in the presence of certain mutations conferring low level fluoroquinolone resistance. Mfxh may cause strong QT prolongation.